共 31 条
The interleukin-6/Janus kinase/STAT3 pathway in pleomorphic adenoma and carcinoma ex pleomorphic adenoma of the lacrimal gland
被引:13
作者:
Andreasen, Simon
[1
,2
,3
]
Heegaard, Steffen
[4
,5
]
Grauslund, Morten
[4
]
Homoe, Preben
[2
,3
]
机构:
[1] Rigshosp, Dept Otorhinolaryngol Head & Neck Surg & Audiol, Copenhagen, Denmark
[2] Koge Univ Hosp, Dept Otorhinolaryngol & Maxillofacial Surg, Lykkebaekvej 1, DK-4600 Koge, Denmark
[3] Univ Copenhagen, Copenhagen, Denmark
[4] Rigshosp, Dept Pathol, Copenhagen, Denmark
[5] Rigshosp Glostrup, Dept Ophthalmol, Copenhagen, Denmark
关键词:
carcinoma ex pleomorphic adenoma;
Interleukin-6;
JAK;
lacrimal gland;
pleomorphic adenoma;
STAT3;
BREAST-CANCER CELLS;
SIGNAL TRANSDUCER;
SALIVARY-GLAND;
ACTIVATION;
EXPRESSION;
CYCLIN-D1;
PHENOTYPE;
PROTEIN;
ORIGIN;
D O I:
10.1111/aos.13122
中图分类号:
R77 [眼科学];
学科分类号:
100212 ;
摘要:
PurposePleomorphic adenoma (PA) is the most common tumour of the lacrimal gland, but very little is known about its biology. It has a tendency to recur and an ability to transform into the high-grade malignancy carcinoma ex pleomorphic adenoma (ca-ex-PA), which is also largely unexplored. In this study, we examine the expression of the interleukin-6/Janus kinase/STAT3 (IL-6/JAK/STAT3) pathway components in PA and ca-ex-PA. MethodsSixteen PAs and two ca-ex-PAs were examined with immunohistochemistry. Seven PAs were subjected to microdissection and subsequent qPCR. ResultsThe IL-6/JAK/STAT3 pathway was overexpressed in PA compared to normal lacrimal gland. Overexpression of phosphorylated JAK1 (p-JAK1) and cyclin D1 was significantly overexpressed in ductal cells compared with myoepithelial cells in PA. A shift from p-JAK1 to p-JAK2 and p-Tyk2 overexpression was seen between PA and ca-ex-PA, combined with a high p-STAT3 expression in the latter. ConclusionThe IL-6/JAK/STAT3 pathway is overexpressed in PA, and this overexpression was even more pronounced in ca-ex-PA, with a shift in the JAKs mediating STAT3 phosphorylation. Future studies are needed to clarify whether PA and ca-ex-PA could be treated with targeted therapy directed against components of the IL-6/JAK/STAT3 pathway.
引用
收藏
页码:798 / 804
页数:7
相关论文